HeartSciences reports Q1 FY2026 with $2.8M cash; launches MyoVista Insights platform

HeartSciences Inc.

No meaningful revenue for Q1 FY2026; cash and equivalents $2.8M, shareholders' equity $3.1M as of July 31, 2025.
Post-quarter raised $0.8M via Reg A+ and exchanged $0.7M debt into equity, strengthening balance sheet.
FDA granted Breakthrough Device designation for aortic stenosis ECG algorithm; now holds 44 granted patents.
Launched MyoVista Insights cloud-native platform; phased rollout began May 2025.
Separate FDA submissions planned for MyoVista wavECG device and algorithm, targeting clearances in 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.